Dr. Marcelo Kremenchutzky, Director of the MS Clinic in London, Ontario, interviews researchers and clinicians at MSBoston 2014, the joint meeting of the Americas and European Committee for Treatment and Research in MS (ACTRIMS/ECTRIMS).
Neurology
Toward a new standard in MS disease control
October 22, 2014REVIEWER: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada
Redefining therapeutic efficacy
Conclusions
New data on novel and emerging therapies were the centrepiece of the 2014 joint meeting of the Americas and European Committee for Research and Treatment of Multiple Sclerosis (ACTRIMS/ECTRIMS), with results suggesting that clinical standards are being redefined for optimal disease control in relapsing-remitting multiple sclerosis (RRMS). Read More
Poor adherence to migraine prophylaxis
October 8, 2014Short-term adherence to migraine prophylaxis is poor, with about one-half of patients stopping their medication within a year, according to the results of a systematic review (Hepp et al. J Manag Care Pharm 2014;20:22-33). Read More
New data for daclizumab in MS
September 24, 2014Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand. Read More
Environmental factors in MS: Air and vitamin D
September 13, 2014REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Few studies have examined the potential impact of ambient air quality and airborne particulates on multiple sclerosis. A decade ago, a study in Finland suggested that the frequency of MS relapses was higher with increasing levels of inhaled particulates (Oikonen et al. Neuroepidemiology 2003;22:95-99). Read More